Clinical Trial Update: Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating furmonertinib in NSCLC patients with EGFR exon 20 insertion mutations is ongoing; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: NSCLC | Phase 1 | Status: ACTIVE_NOT_RECRUITING